Disease · MONDO_0019340
Trials16
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
1 to 16 of 16
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00848107 | Open-Label Study of Oral Treprostinil in Digital Ulcers | Phase 2 | 115 | 2014-02-07 | Systemic Sclerosis | TREPROSTINIL DIOLAMINE | Its record names the disease | ClinicalTrials.gov |
| NCT01445821 | Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial | Phase 3 | 44 | 2020-07-23 | Scleroderma, Systemic | CYCLOPHOSPHAMIDE, FILGRASTIM, FLUDARABINE | Its record names the disease | ClinicalTrials.gov |
| NCT01166139 | Nilotinib in the Treatment of Systemic Sclerosis | Phase 2 | 10 | 2017-10-04 | Systemic Sclerosis | NILOTINIB | Its record names the disease | ClinicalTrials.gov |
| NCT02503644 | Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis | Phase 2 | 145 | Scleroderma, Diffuse, Diffuse Cutaneous Systemic Sclerosis | LANIFIBRANOR | Its record names the disease | ClinicalTrials.gov | |
| NCT01295736 | Sildenafil Effect on Digital Ulcer Healing in sClerodErma SEDUCE STUDY | Phase 3 | 84 | Systemic Scleroderma | SILDENAFIL | Its record names the disease | ClinicalTrials.gov | |
| NCT05963048 | Rituxmab Versus IL-6 in Treating ILD | Phase 2/3 | 60 | Interstitial Lung Disease, Scleroderma | RITUXIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT04200755 | Clinical Trial to Evaluate Efficacy and Safety of Dupilumab in Localized Scleroderma | Phase 2 | 45 | Localized Scleroderma | DUPILUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT00930683 | A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma | Phase 1 | 34 | Scleroderma | ANIFROLUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT04797286 | Sildenafil for Early Pulmonary Vascular Disease in Scleroderma | Phase 2 | 30 | Scleroderma, Mildly Elevated Pulmonary Pressures | SILDENAFIL | Its record names the disease | ClinicalTrials.gov | |
| NCT00740285 | Effectiveness and Safety of Lidocaine for Scleroderma | Phase 2/3 | 26 | Scleroderma | LIDOCAINE | Its record names the disease | ClinicalTrials.gov | |
| NCT01284322 | Fresolimumab In Systemic Sclerosis | Phase 1 | 18 | Diffuse Systemic Sclerosis | FRESOLIMUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT00241189 | Rapamycin vs Methotrexate in Diffuse SSc | Phase 1/2 | 17 | Systemic Sclerosis | METHOTREXATE, SIROLIMUS | Its record names the disease | ClinicalTrials.gov | |
| NCT02426229 | Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma | Phase 1 | 15 | Scleroderma, Interstitial Lung Disease | DABIGATRAN ETEXILATE | Its record names the disease | ClinicalTrials.gov | |
| NCT01545427 | Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma | Phase 2 | 10 | Scleroderma | IMATINIB | Its record names the disease | ClinicalTrials.gov | |
| NCT02166229 | Divalproex Sodium in the Treatment of the Cutaneous Manifestations of Scleroderma | Phase 1/2 | 0 | Scleroderma, Systemic Sclerosis | DIVALPROEX SODIUM | Its record names the disease | ClinicalTrials.gov | |
| NCT03679845 | Study to Assess Sarilumab in Halting Progression of Morphea | Phase 1/2 | 0 | Morphea, Plaque Form | SARILUMAB | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0019340/trials